Table 1 Inhibition of fibrinogen binding... | American Society of Hematology

Table 1

Inhibition of fibrinogen binding to recombinant αIIbβ3* containing a human, rat, or chimeric human/rat α subunit by 1 mM RGDS

	% inhibition†
WT α subunits
Human	85.7 ± 1.2
Rat	23.8 ± 12.7
αIIb W3:4-1 substitutions (rat→human)
ΔV¹⁵⁶	83.7 ± 4.4
E¹⁵⁷S	60.0 ± 3.6
D¹⁵⁹G	45.9 ± 1.4
W¹⁶²G	60.5 ± 4.6
αIIb W4:4-1 substitutions (rat→human)
E²²⁹V	91.1 ± 4.7
Y²³⁰F	82.2 ± 6.1
D²³²H	31.1 ± 3.2
D²³²N	36.1 ± 3.3
D²³²E	76.2 ± 2.3
D²³²A	NFB‡
Combined αIIb substitutions (rat→human)
V¹⁵⁶D,D²³²H	39.1 ± 11.4
W3:4-1, D²³²H	30.9

	% inhibition†
WT α subunits
Human	85.7 ± 1.2
Rat	23.8 ± 12.7
αIIb W3:4-1 substitutions (rat→human)
ΔV¹⁵⁶	83.7 ± 4.4
E¹⁵⁷S	60.0 ± 3.6
D¹⁵⁹G	45.9 ± 1.4
W¹⁶²G	60.5 ± 4.6
αIIb W4:4-1 substitutions (rat→human)
E²²⁹V	91.1 ± 4.7
Y²³⁰F	82.2 ± 6.1
D²³²H	31.1 ± 3.2
D²³²N	36.1 ± 3.3
D²³²E	76.2 ± 2.3
D²³²A	NFB‡
Combined αIIb substitutions (rat→human)
V¹⁵⁶D,D²³²H	39.1 ± 11.4
W3:4-1, D²³²H	30.9

Recombinant αIIbβ3 was expressed in CHO cells and was activated using DTT as described in “Fibrinogen binding to CHO cells expressing αIIbβ3.”

The results are the mean and 1 SE of three or more experiments.

NFB indicates no fibrinogen binding.